TRUST-II: A global phase II study for taletrectinib in <i>ROS1</i> fusion–positive lung cancer and other solid tumors.Misako Nagasaka, Yuichiro Ohe, Noriko Yanagitani et al.|Journal of Clinical Oncology|2022Cited by 4
PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.Daniel A. Vaena, James K. Schwarz, Jorge Chaves et al.|Journal of Clinical Oncology|2018Cited by 3